Advanced Breast Cancer Drug Eribulin Not Recommended for NHS Use

breast-cancer-drugAs per recent reports, it has been claimed that NICE has nodded against a novel breast cancer drug, dubbed eribulin, for use by NHS on a regular basis.

In this regard, final draft guidance was released by the National Institute for Health and Clinical Excellence (NICE) as per which, it does not advise a novel drug termed ‘eribulin’ for use against advanced stages of breast cancer. The decision clearly implies that patients will not be having regular access to the said treatment till the time they hold private medical insurance.

While expressing his opinion in this regard, the Chief Executive of NICE, Sir Andrew Dillon revealed: “Although the evidence presented to the independent advisory committee indicated that eribulin may help some patients live for a little longer”.

He added that it also resulted in causing more unwanted side effects as compared to various other treatments which are already accessible for one and all, and the consequences on health-related standards of life was never assessed precisely.

The drug has been developed by pharmaceutical firm Eisai, and it is meant for treating patients with metastatic or locally advanced breast cancer, especially those who have already experienced at least chemotherapy session.

These patients are generally prescribed with capecitabine, vinorelbine and in some special cases, doctors are even prescribing gemcitabine. Sir Andrew further asserted that even if NICE has approved the novel drug, it would be quite improbable to swap vinorelbine and capecitabine, mainly due to its side-effects.

While expressing her disappointment in this regard, a clinical nurse specialist at the charity termed ‘Breast Cancer Care’, Tara Beaumont claimed that the medicine has already been proven for extending life by “several valuable months”.

In addition, she called for investment in the fields of nursing care and treatment for improving the quality of life for people suffering from breast cancer.